Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1986 2
1987 1
1990 1
1991 2
1992 2
1994 1
1995 1
1996 1
1997 2
2000 1
2001 2
2002 1
2003 1
2004 1
2005 1
2006 4
2007 3
2008 4
2009 2
2010 1
2011 1
2014 1
2015 2
2016 1
2017 1
2021 2
2023 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Computational reactive-diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib.
Schettini F, De Bonis MV, Strina C, Milani M, Ziglioli N, Aguggini S, Ciliberto I, Azzini C, Barbieri G, Cervoni V, Cappelletti MR, Ferrero G, Ungari M, Locci M, Paris I, Scambia G, Ruocco G, Generali D. Schettini F, et al. Among authors: aguggini s. Sci Rep. 2023 Jul 24;13(1):11951. doi: 10.1038/s41598-023-38760-z. Sci Rep. 2023. PMID: 37488154 Free PMC article. Clinical Trial.
Driving parameters governing the mathematical model were selected with Pearson's correlations. Discrepancies between actual and computed SUV(max) values were assessed with Student's t test and Wilcoxon rank sum test. The correlation between post-olaparib true and co …
Driving parameters governing the mathematical model were selected with Pearson's correlations. Discrepancies between actual and compu …
Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study.
Schettini F, Saracchini S, Bassini A, Marus W, Corsetti S, Specogna I, Bertola M, Micheli E, Wirtz RM, Laible M, Şahin U, Strina C, Milani M, Aguggini S, Tancredi R, Fiorio E, Sulfaro S, Generali D. Schettini F, et al. Among authors: aguggini s. Breast. 2024 Aug;76:103753. doi: 10.1016/j.breast.2024.103753. Epub 2024 May 25. Breast. 2024. PMID: 38815444 Free PMC article.
This retrospective study assessed the mRNA-based MammaTyper assay's capability of predicting pCR with NACT, and ER, PR, Ki67, and HER2 status at immunohistochemical (IHC) through transcriptomics. ...
This retrospective study assessed the mRNA-based MammaTyper assay's capability of predicting pCR with NACT, and ER, PR, Ki67, and HER …
PAF and the role of the vagus nerve in the breathing pattern of the pig.
Clement MG, Albertini M, Dimori M, Aguggini G. Clement MG, et al. Among authors: aguggini g. Prostaglandins Leukot Essent Fatty Acids. 1992 Feb;45(2):143-9. doi: 10.1016/0952-3278(92)90231-7. Prostaglandins Leukot Essent Fatty Acids. 1992. PMID: 1561234
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial.
Schettini F, Corona SP, Giudici F, Strina C, Sirico M, Bernocchi O, Milani M, Ziglioli N, Aguggini S, Azzini C, Barbieri G, Cervoni V, Cappelletti MR, Molteni A, Lazzari MC, Ferrero G, Ungari M, Marasco E, Bruson A, Xumerle L, Zago E, Cerra D, Loddo M, Williams GH, Paris I, Scambia G, Generali D. Schettini F, et al. Among authors: aguggini s. Front Oncol. 2021 Jun 28;11:686776. doi: 10.3389/fonc.2021.686776. eCollection 2021. Front Oncol. 2021. PMID: 34262869 Free PMC article.
Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
Mele T, Generali D, Fox S, Brizzi MP, Bersiga A, Milani M, Allevi G, Bonardi S, Aguggini S, Volante M, Dogliotti L, Bottini A, Harris A, Berruti A. Mele T, et al. Among authors: aguggini s. Breast Cancer Res Treat. 2010 Oct;123(3):795-804. doi: 10.1007/s10549-010-1063-0. Epub 2010 Aug 3. Breast Cancer Res Treat. 2010. PMID: 20680681 Clinical Trial.
Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer.
Milani M, Venturini S, Bonardi S, Allevi G, Strina C, Cappelletti MR, Corona SP, Aguggini S, Bottini A, Berruti A, Jubb A, Campo L, Harris AL, Gatter K, Fox SB, Generali D, Roviello G. Milani M, et al. Among authors: aguggini s. Oncotarget. 2017 Aug 14;8(45):78870-78881. doi: 10.18632/oncotarget.20239. eCollection 2017 Oct 3. Oncotarget. 2017. PMID: 29108271 Free PMC article.
Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer.
Generali D, Fox SB, Berruti A, Moore JW, Brizzi MP, Patel N, Allevi G, Bonardi S, Aguggini S, Bersiga A, Campo L, Dogliotti L, Bottini A, Harris AL. Generali D, et al. Among authors: aguggini s. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):550-8. doi: 10.1158/1078-0432.CCR-06-1266. Clin Cancer Res. 2007. PMID: 17255277 Clinical Trial.
41 results